Status:
COMPLETED
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Lead Sponsor:
Fudan University
Conditions:
Cancer of Unknown Primary Site
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This study is designed to evaluate the value of tissue-of-origin (ORIGIN-PanCA○R) profiling in predicting primary site and directing therapy in patients with cancer of unknown primary.
Eligibility Criteria
Inclusion
- had a diagnosis of cancer of unknown primary (CUP) after a standard evaluation (medical history, physical examination, blood counts, chemistry profile, chest/abdomen computed tomography scans, positron emission tomography scan, and directed evaluation of all symptomatic areas). Patients were required to have one of the following histologies: adenocarcinoma, poorly differentiated neoplasms, poorly differentiated carcinoma, squamous carcinoma. Sufficient archived biopsy tissue from a surgical or core needle biopsy was required to perform the molecular profiling assay. Eastern Cooperative Oncology Group performance status of 0 to 2; no previous systemic therapy; measurable or evaluable disease (RECIST); and adequate organ function.
Exclusion
- carcinoma limited to single site which can be potentially cured by surgery of radiotherapy.patients with symptomatic brain metastases, active clinical severe infection
Key Trial Info
Start Date :
September 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2021
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT03278600
Start Date
September 18 2017
End Date
March 18 2021
Last Update
January 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Cancer Hospital
Shanghai, China, 200032